WO2018230960A3 - 신규한 비피도박테리움 비피덤 균주 및 균주 유래 다당체 - Google Patents

신규한 비피도박테리움 비피덤 균주 및 균주 유래 다당체 Download PDF

Info

Publication number
WO2018230960A3
WO2018230960A3 PCT/KR2018/006700 KR2018006700W WO2018230960A3 WO 2018230960 A3 WO2018230960 A3 WO 2018230960A3 KR 2018006700 W KR2018006700 W KR 2018006700W WO 2018230960 A3 WO2018230960 A3 WO 2018230960A3
Authority
WO
WIPO (PCT)
Prior art keywords
strain
polysaccharide
bifidobacterium bifidum
effective ingredient
cells
Prior art date
Application number
PCT/KR2018/006700
Other languages
English (en)
French (fr)
Other versions
WO2018230960A2 (ko
Inventor
임신혁
베르마라비
이창헌
Original Assignee
기초과학연구원
포항공과대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 기초과학연구원, 포항공과대학교 산학협력단 filed Critical 기초과학연구원
Priority to US16/621,442 priority Critical patent/US11660312B2/en
Priority to JP2019569943A priority patent/JP7027462B2/ja
Priority to CN201880046063.7A priority patent/CN113166712A/zh
Priority to EP18817528.5A priority patent/EP3650533A4/en
Publication of WO2018230960A2 publication Critical patent/WO2018230960A2/ko
Publication of WO2018230960A3 publication Critical patent/WO2018230960A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/50—Polysaccharides, gums
    • A23V2250/502—Gums
    • A23V2250/5034—Beta-Glucan
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/517—Bifidum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Materials Engineering (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

본 발명은 조절 T 세포 (Treg)를 유도하는 비피도박테리움 비피덤 및 비피도박테리움 비피덤에서 유래된 다당체 및 다당체를 생산하는 프로바이오틱 균주에 관한 것으로, 더욱 자세하게는 β-1-6-glucan을 유효성분으로 함유하는 다당체, β-1-6-glucan을 생산하는 프로바이오틱 균주, 상기 다당체 또는 균주를 유효성분으로 함유하는 면역 질환 또는 염증성 질환의 개선용 식품, 치료제, 상기 다당체 또는 균주를 처리하여 유도 조절 T 세포 (iTreg)를 제조하는 방법 및 이에 의해 제조된 유도 조절 T 세포를 포함하는 면역 질환 또는 염증성 질환의 예방 또는 치료용 세포치료제에 관한 것이다.
PCT/KR2018/006700 2017-06-14 2018-06-14 신규한 비피도박테리움 비피덤 균주 및 균주 유래 다당체 WO2018230960A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US16/621,442 US11660312B2 (en) 2017-06-14 2018-06-14 Bifidobacterium bifidum strain and strain-derived polysaccharide
JP2019569943A JP7027462B2 (ja) 2017-06-14 2018-06-14 新規のビフィドバクテリウムビフィダム菌株及び菌株由来多糖体
CN201880046063.7A CN113166712A (zh) 2017-06-14 2018-06-14 新型两歧双歧杆菌菌株和菌株来源的多糖
EP18817528.5A EP3650533A4 (en) 2017-06-14 2018-06-14 NEW STRAIN DEBIFIDOBACTERIUM BIFIDUM

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170075079 2017-06-14
KR10-2017-0075079 2017-06-14

Publications (2)

Publication Number Publication Date
WO2018230960A2 WO2018230960A2 (ko) 2018-12-20
WO2018230960A3 true WO2018230960A3 (ko) 2019-03-28

Family

ID=64658709

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/006700 WO2018230960A2 (ko) 2017-06-14 2018-06-14 신규한 비피도박테리움 비피덤 균주 및 균주 유래 다당체

Country Status (6)

Country Link
US (1) US11660312B2 (ko)
EP (1) EP3650533A4 (ko)
JP (2) JP7027462B2 (ko)
KR (3) KR102205829B1 (ko)
CN (1) CN113166712A (ko)
WO (1) WO2018230960A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110468061B (zh) * 2018-05-11 2024-03-08 韩国亿诺生物有限公司 具有预防或治疗癌症的效果的新型菌株
EP4088729A4 (en) 2020-01-10 2023-08-30 Immunobiome Inc. NEW STRAIN OF LACTOBACILLUS PLANTARUM, POLYSACCHARIDES DERIVED FROM THE STRAIN AND THEIR USE
KR20220069248A (ko) * 2020-11-20 2022-05-27 가톨릭대학교 산학협력단 비피도박테리움 속을 유효성분으로 포함하는 피부경화증에 대한 테라그노시스용 조성물
CN115261426B (zh) * 2022-09-26 2023-01-03 东北农业大学 一种具有抗氧化能力的两歧双歧杆菌e3胞外多糖
KR20240122658A (ko) * 2023-02-03 2024-08-13 이뮤노바이옴 주식회사 이식 거부 반응의 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1965809B1 (en) * 2005-11-21 2009-09-09 Bioatlantis Limited Compositions to improve gut health and animal performance comprising beta-glucans and alfa-fucans
US20150152454A1 (en) * 2012-07-17 2015-06-04 Shigenobu Miura Method for producing beta-glucan
US20170081428A1 (en) * 2014-05-08 2017-03-23 Immunexcite, Inc. Immunomodulating beta-1,6-d-glucans

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1260227A1 (en) * 2001-05-23 2002-11-27 Societe Des Produits Nestle S.A. Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria
KR100720706B1 (ko) * 2005-12-30 2007-05-21 인제대학교 산학협력단 면역조절활성 또는 항암활성을 갖는 아가리쿠스로부터추출한 β-글루칸 또는 올리고당류
JP5184033B2 (ja) 2007-10-03 2013-04-17 株式会社Ａｄｅｋａ 免疫調節剤
US8617823B2 (en) * 2008-04-29 2013-12-31 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
US9738731B2 (en) 2013-03-08 2017-08-22 Tokyo University Of Science Foundation Lactic acid bacterium growth enhancer, regulatory T-cell number increasing agent, method of enhancing growth of lactic acid bacterium, method of increasing number of regulatory T-cells, method of evaluating regulatory T-cell number increasing effect, and method of evaluating lactic acid growth enhancing effect
CN112195128B (zh) * 2014-08-29 2023-05-02 科.汉森有限公司 益生菌青春双歧杆菌菌株
US20170369570A1 (en) * 2015-01-20 2017-12-28 Immunexcite, Inc. Compositions and methods for cancer immunotherapy
CA2990618A1 (en) 2015-06-22 2016-12-29 Esen SEFIK Induction of lamina propria regulatory t cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1965809B1 (en) * 2005-11-21 2009-09-09 Bioatlantis Limited Compositions to improve gut health and animal performance comprising beta-glucans and alfa-fucans
US20150152454A1 (en) * 2012-07-17 2015-06-04 Shigenobu Miura Method for producing beta-glucan
US20170081428A1 (en) * 2014-05-08 2017-03-23 Immunexcite, Inc. Immunomodulating beta-1,6-d-glucans

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IM, SIN-HYEOG: "Reprogramming of the immune system by rationally selected probiotics", UNIST-LIFE SCIENCES, 7 June 2018 (2018-06-07), BLDG 110 Room N104, XP055584695, Retrieved from the Internet <URL:https://seminars.ibs.re.kr/bbs/board.php?bo_table=seminar&pos=-2&wr_id=230> *
LOPEZ ET AL.: "Immune response to Bifidobacterium bifidum strains support Treg/Th17 plasticityen", PLOS ONE, vol. 6, no. 9, 22 September 2011 (2011-09-22), pages e24776, XP055584689 *
SASSAKI, GUILHERME L.: "Pustulan and branched beta-gatactofuranan from the phytopathogenic fungus Guignardia citricarpa, excreted from media containing glucose and sucrose", CARBOHYDRATE POLYMERS, vol. 48, no. 4, June 2002 (2002-06-01), pages 385 - 389, XP004339327, ISSN: 0144-8617, DOI: 10.1016/S0144-8617(01)00286-7 *

Also Published As

Publication number Publication date
KR102205829B1 (ko) 2021-01-21
KR20180136395A (ko) 2018-12-24
JP2021118687A (ja) 2021-08-12
JP2020525570A (ja) 2020-08-27
WO2018230960A2 (ko) 2018-12-20
JP7027462B2 (ja) 2022-03-01
KR20190088447A (ko) 2019-07-26
KR102098833B1 (ko) 2020-04-08
CN113166712A (zh) 2021-07-23
JP7250059B2 (ja) 2023-03-31
US11660312B2 (en) 2023-05-30
EP3650533A4 (en) 2021-07-21
EP3650533A2 (en) 2020-05-13
KR20200085695A (ko) 2020-07-15
US20210077521A1 (en) 2021-03-18
KR102248111B1 (ko) 2021-05-04

Similar Documents

Publication Publication Date Title
WO2018230960A3 (ko) 신규한 비피도박테리움 비피덤 균주 및 균주 유래 다당체
AU2018338608A1 (en) Methods, compositions, and implantable elements comprising active cells
MX2017008813A (es) Polvo de coleopteros.
EP4424319A3 (en) Novel lactobacillus having various functions, and use thereof
MY187060A (en) Bifidobacteria as probiotic foundation species of gut microbiota
MY191508A (en) Production of beta-lactoglobulin preparations
PH12015500106B1 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
WO2016210384A3 (en) Bacteria engineered to treat metabolic diseases
WO2014018596A3 (en) Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides
WO2019066577A3 (ko) 짧은 사슬 지방산 생성 장내 세균 군집의 변화를 이용한 알코올성 간 질환의 진단 및 치료용 조성물
MY197201A (en) Novel probiotics bifidobacteria strains
WO2016190683A8 (ko) 길경 추출물을 함유하는 근육 질환 예방 및 치료용 또는 근 기능 개선용 조성물
MX2022011167A (es) Metodos para mejorar las respuestas inmune innata y/o deteccion de patogenos de la mucosa mediante oligosacaridos de la leche humana.
WO2017139697A8 (en) Bacteria engineered to treat diseases associated with hyperammonemia
MX2021013030A (es) Cepas bacterianas probioticas que producen acidos grasos de cadena corta y composiciones que las comprenden.
MX2017007654A (es) Cepas probioticas con capacidad de absorber colesterol, métodos y usos de las mismas.
EP4295902A3 (en) Probiotic bacterial strains producing antimicrobial proteins and compositions comprising these for use in the treatment of clostridium difficile infection
MY186323A (en) Lactobacillus salivarius for the treatment of mastitis
PH12018500993A1 (en) Nutritional compositions comprising lactobacillus rhamnosus gg, as well as dietary butyrate and/or a compound for stimulating formation of endogenous butyrate
MX2016001635A (es) Probiotico para el llanto infantil excesivo.
WO2012065153A3 (en) Modified immune-modulating particles
WO2015170158A8 (en) Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation
MX2019010228A (es) Composición para liberación controlada de sustancias fisiológicamente activas y proceso para su preparación.
NZ628451A (en) Dehydrated plant-derived products and methods for making the same
MX2017007969A (es) Bacterias de acido lactico y su uso para el tratamiento de mastitis.

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2019569943

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018817528

Country of ref document: EP

Effective date: 20200114

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18817528

Country of ref document: EP

Kind code of ref document: A2